Vaccine Presentation in the USA: Economics of Prefilled Syringes versus Multidose Vials for Influenza Vaccination

Claudia C Pereira; David Bishai

Disclosures

Expert Rev Vaccines. 2010;9(11):1343-1349. 

In This Article

What is the Current Status of MDV & PFS Use in Influenza Vaccination the USA?

A variety of factors have led to a growing number of manufacturers of vaccines and other injectables offering PFS platforms for their products. Over the last decade, the US market for PFSs grew at a rate of approximately 20% per year.[101] For vaccines, efficiency and perceived safety drive the growth of PFS presentations. Despite the lack of evidence of toxic effects of thimerosal, the public perception of risk owing to this preservative has shifted many providers away from MDVs towards preservative-free PFSs. In 2004, the Institute of Medicine's Immunization Safety Review committee rejected any causal link between thimerosal and autism.[4] Despite such information, many parents and patients still exhibit concerns over the use of vaccines in general,[5,6] and from MDVs in particular.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....